HealthEquity (NASDAQ:HQY) Price Target Cut to $110.00 by Analysts at BTIG Research

HealthEquity (NASDAQ:HQY) had its price target cut by BTIG Research from $130.00 to $110.00 in a report released on Tuesday,Benzinga reports. They currently have a buy rating on the stock.

A number of other brokerages also recently issued reports on HQY. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $120.00 price target on shares of HealthEquity in a research report on Friday, December 5th. Barclays assumed coverage on shares of HealthEquity in a research note on Monday, December 8th. They issued an “overweight” rating and a $118.00 price target for the company. KeyCorp lifted their price objective on shares of HealthEquity from $120.00 to $125.00 and gave the stock an “overweight” rating in a report on Thursday, January 8th. Weiss Ratings reissued a “hold (c+)” rating on shares of HealthEquity in a research note on Thursday, January 22nd. Finally, Wall Street Zen upgraded HealthEquity from a “hold” rating to a “buy” rating in a research report on Monday, January 19th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $116.13.

HealthEquity Stock Performance

NASDAQ HQY opened at $74.36 on Tuesday. The company’s 50 day simple moving average is $87.65 and its two-hundred day simple moving average is $91.95. The company has a debt-to-equity ratio of 0.46, a current ratio of 4.13 and a quick ratio of 4.13. HealthEquity has a 1 year low of $72.76 and a 1 year high of $116.65. The stock has a market capitalization of $6.35 billion, a PE ratio of 34.11, a P/E/G ratio of 0.92 and a beta of 0.24.

HealthEquity (NASDAQ:HQY) last released its quarterly earnings results on Wednesday, December 3rd. The company reported $1.01 earnings per share for the quarter, topping the consensus estimate of $0.90 by $0.11. The firm had revenue of $322.16 million for the quarter, compared to analysts’ expectations of $320.92 million. HealthEquity had a net margin of 14.86% and a return on equity of 12.94%. The business’s quarterly revenue was up 7.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.78 earnings per share. HealthEquity has set its FY 2026 guidance at 3.870-3.950 EPS. Analysts predict that HealthEquity will post 2.32 earnings per share for the current fiscal year.

Insider Activity at HealthEquity

In related news, EVP Elimelech Rosner sold 10,959 shares of the company’s stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $95.45, for a total transaction of $1,046,036.55. Following the completion of the sale, the executive vice president directly owned 45,742 shares in the company, valued at $4,366,073.90. This represents a 19.33% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Delano Ladd sold 1,500 shares of the firm’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $94.72, for a total transaction of $142,080.00. Following the completion of the sale, the executive vice president directly owned 73,979 shares in the company, valued at approximately $7,007,290.88. This trade represents a 1.99% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 13,959 shares of company stock worth $1,344,957. 1.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On HealthEquity

Large investors have recently modified their holdings of the stock. Xponance Inc. boosted its position in HealthEquity by 0.8% during the 3rd quarter. Xponance Inc. now owns 12,265 shares of the company’s stock valued at $1,162,000 after acquiring an additional 102 shares in the last quarter. Nisa Investment Advisors LLC lifted its stake in shares of HealthEquity by 2.9% in the 2nd quarter. Nisa Investment Advisors LLC now owns 3,787 shares of the company’s stock valued at $397,000 after purchasing an additional 108 shares during the period. Advisors Asset Management Inc. boosted its position in shares of HealthEquity by 4.7% during the second quarter. Advisors Asset Management Inc. now owns 2,437 shares of the company’s stock valued at $255,000 after purchasing an additional 110 shares in the last quarter. Truist Financial Corp grew its stake in HealthEquity by 4.9% in the fourth quarter. Truist Financial Corp now owns 2,537 shares of the company’s stock worth $232,000 after purchasing an additional 119 shares during the period. Finally, Fiduciary Trust Co raised its holdings in HealthEquity by 3.4% in the third quarter. Fiduciary Trust Co now owns 3,669 shares of the company’s stock worth $348,000 after purchasing an additional 120 shares in the last quarter. Institutional investors own 99.55% of the company’s stock.

HealthEquity Company Profile

HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.

Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.